Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler  by Bodzenta-Lukaszyk, Anna et al.
Respiratory Medicine (2011) 105, 674e682ava i lab le at www.sc iencedi rect .com
journal homepage : www.e lsev ie r . com/ loca te / rmedEfficacy and safety of fluticasone and formoterol
in a single pressurized metered dose inhalerAnna Bodzenta-Lukaszyk a,*, Gra _zyna Pulka b, Andrzej Dymek c,
Dragos Bumbacea d, Tammy McIver e, Birgit Schwab f, Heikki Mansikka eaDepartment of Allergology and Internal Medicine, Medical University of Białystok, M.Sklodowskiej-Curie 24 A,
15-276 Bialystok, Poland
bDepartment of Allergology and Internal Medicine ALL e MED, Krakow, Poland
cMedical Center Lucyna Andrzej Dymek, Strzelce Opolskie, Poland
dDepartment of Pulmonology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
eMundipharma Research Limited, Cambridge, UK
fMundipharma Research GmbH & Co. KG, Limburg, Germany
Received 7 June 2010; accepted 12 November 2010
Available online 31 December 2010KEYWORDS
Combination therapy;
Asthma;
Fluticasone;
Formoterol;
pMDI;
flutiform* Corresponding author. Tel.: þ48 8
E-mail address: abodzentalukaszyk
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2010.11.011Summary
Background: Fluticasone and formoterol are well established medications for the treatment of
asthma. This study (Clinicaltrials.gov identifier: NCT00734318) compares the efficacy and
safety of a combination of these drugs in a single inhaler (fluticasone/formoterol) versus the
individual components (fluticasone þ formoterol).
Methods: Patients aged  18 years (n Z 620) with a history of severe, persistent reversible
asthma for  6 months prior to screening were included in this randomized, double-blind
study, which consisted of a screening phase of up to 5 days, a 2-week run-in phase and an
8-week treatment period.
Results: Fluticasone/formoterol (500/20 mg, b.i.d.) was at least as effective as
fluticasone þ formoterol (500 mg þ 24 mg, b.i.d.) with respect to the primary outcome
measure: there were similar increases in mean pre-morning dose forced expiratory volume
in the first second (FEV1) in these two groups. Fluticasone/formoterol (500/20 mg, b.i.d.) also
demonstrated similar efficacy to fluticasone þ formoterol in terms of change in mean FEV1
from baseline pre-morning dose to 2 h post-morning dose at week 8, as well as for several
secondary parameters. Fluticasone/formoterol (500/20 mg, b.i.d.) demonstrated superiority
to fluticasone monotherapy (500 mg, b.i.d.) and fluticasone/formoterol (100/10 mg, b.i.d.)
for several secondary efficacy parameters. Fluticasone/formoterol had a similar safety and
tolerability profile to fluticasone þ formoterol.57468373; fax: þ48 857468509.
@gmail.com (A. Bodzenta-Lukaszyk).
0 Elsevier Ltd. All rights reserved.
Fluticasone/formoterol combination vs. individual components 675Conclusion: This study demonstrated that the fluticasone/formoterol combination is at least
as effective as its components administered concurrently from separate inhalers. Flutica-
sone/formoterol (500/20 mg, b.i.d.) showed superior efficacy to its inhaled corticosteroid
component alone and the efficacy of fluticasone/formoterol was dose-dependent for several
clinically important parameters.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
In most countries, asthma prevalence is increasing, and the
disease continues to be associated with substantial
morbidity.1 The global burden is reflected in the number of
global disability adjusted life-years lost to asthma being
similar to that lost to diabetes.1 Consequently, some
government health strategies recognize asthma as a priority
disorder.1 Over half of the total economic cost of asthmamay
be due to suboptimal control.2,3
Guidelines recommend a step-wise treatment approach
to achieve optimal asthma control. When the disease is not
controlled on low-to-medium dose inhaled corticosteroids
(ICSs) alone, combination therapy with an ICS and a long-
acting b2-agonist (LABA) should be initiated.
4 It is nowwidely
accepted that dual therapy as a single inhaler combination is
likely to improve patient adherence compared with mono-
therapy regimens.5,6 There is also evidence to suggest that an
ICS and a LABA, when administered concurrently, act
synergistically at the molecular level, enhancing the thera-
peutic effect.5,6
Despite the availability of efficacious combination ther-
apies, asthma control remains suboptimal in many
patients7e10 and many continue to experience asthma
symptoms that may require unscheduled emergency care or
hospital visits.7,8,11 Switching between therapies and inhaler
devices is common and may indicate that there is a need for
alternative treatmentoptions.12 Factors contributing topoor
asthma control include insufficient training in inhaler use,
poor handling of devices and poor matching of devices to
patients’ natural inhalation techniques.13
Optimizing the clinical efficacy of combination therapies
may improve asthma control. The anti-inflammatory effects
of fluticasone are rapid and sustained, and it is an effective
treatment for chronic asthma.14e16 Formoterol is the most
rapidly acting LABAwith a speed of onset of action similar to
that of salbutamol.17 The combination of fluticasone and
formoterol in a single inhaler may have the potential to
increase patient adherence to their therapy regimen as the
patients may perceive the relief of asthma symptoms with
formoterol more rapidly than with other LABAs,11,18 which in
turn may reduce the burden of asthma.19
Fluticasone/formoterol have therefore been combined in
a single hydrofluoroalkane (HFA) pressurized metered dose
inhaler (pMDI; flutiform) for the maintenance treatment of
asthma in patients whose symptoms are not adequately
controlled with an ICS plus an ‘as needed’ inhaled short-
acting b2-agonist, as well as patients whose asthma is already
controlled with both an ICS and a LABA. This study assessed
the efficacy and safety of fluticasone/formoterol versus its
individual componentsadministeredconcurrently in separate
inhalers (fluticasoneþ formoterol) in a phase 3 clinical study.Methods
Study design
This was a double-blind, double-dummy, four-arm, parallel-
group, multinational study conducted at 90 centres across
Europe, and in Israel and India (Clinicaltrials.gov identifier:
NCT00734318). The study was performed in accordance
with the Declaration of Helsinki and Good Clinical Practice
guidelines, and approved by independent ethics commit-
tees. Written informed consent was obtained from all
patients. The study was initiated (first patient, first visit) on
27 August 2008 and was completed (last patient, last visit)
on 15 September 2009.
The study consisted of a screening phase of up to 5 days
to evaluate the eligibility of patients for participation in
the study (as described below), a 2-week run-in phase (that
could be extended for up to a total of 28 days if the patient
failed to meet inclusion criteria), and an 8-week treatment
period. Following the run-in, forced expiratory volume in
the first second (FEV1) was assessed and eligible patients
were randomized (1:1:1:1), using an interactive voice
response system, to one of two doses of fluticasone/for-
moterol (500/20 mg or 100/10 mg twice daily [b.i.d.]),
fluticasone þ formoterol (500 mg þ 24 mg, b.i.d., adminis-
tered concurrently in separate inhalers; hereafter referred
to as fluticasone þ formoterol) or to fluticasone alone
(500 mg, b.i.d.; hereafter referred to as fluticasone).
Patients were stratified according to the severity of their
airway obstruction (stratum 1:  40% to  60% of predicted
FEV1; stratum 2: > 60% to  80% of predicted FEV1), and
allocated evenly across the four treatment groups. Test and
control study medications were administered by pMDI via
a spacer. Depending on whether one or two inhalers were
required to administer the study medication, patients also
received one or two placebo inhalers as appropriate to
maintain blinding during the treatment phase (as inhalers
for fluticasone/formoterol, fluticasone and formoterol
differed in shape and size). Throughout the study, patients
were permitted to take salbutamol (200 mg up to four times
daily, administered without spacer) as rescue medication.
Patients could be withdrawn from the study due to wors-
ening of asthma, which was defined as any of the following:
severe asthma exacerbation requiring treatment (i.e.
emergency treatment, hospitalization, use of oral or
parenteral corticosteroids); decrease in pre-dose FEV1 of
more than 20% of pre-dose FEV1 at the end of run-in phase
(assessed at the study visit); decrease in diurnal pre-dose
peak expiratory flow rates (PEFR) of more than 50% of pre-
dose PEFR at end of run-in (assessed using daily diary data);
use of salbutamol on at least 6 occasions per day on more
than 3 of the 7 days preceding a study visit; night awakenings
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2 of the 7 nights preceding a study visit.
On completion or discontinuation of the study, patients
were followed up by telephone after 14 days for the
reporting of ongoing adverse events (AEs) and any new AEs
that may have occurred.
Study participants
Males and females (aged  18 years) with a history of severe,
persistent reversible asthma for 6months prior to screening
(characterized by treatmentwith an ICS [ 5 00 mg fluticasone
or equivalent ICS dose]) were included in the study. Patients
were required to demonstrate pre-bronchodilator FEV1 of 
40% to 80% of predicted normal values20 (i.e. moderate-to-
severe asthma) and reversibility of  15% in FEV1 after sal-
butamol inhalation at screening in order to be eligible for
randomization. During the run-in, all patients received fluti-
casone 250 mg (b.i.d.) via a pMDI and could take salbutamol
200mg (up to 4-times daily) via a pMDI as rescuemedication. In
order to continue in the study following run-in, patients were
required to have used salbutamol for at least 3 days, and
either had at least 1 night with sleep disturbance or at least 3
dayswith asthma symptomsduring the last 7 days of the run-in
period. Only patients who could demonstrate correct inhaler
technique were entered into the study.
Among the exclusion criteria were: life-threatening
asthma within the past year; hospitalization or emergency
room visit for asthma within the 4 weeks prior to screening;
systemic corticosteroid use within the month prior to
screening; omalizumab use within the past 6 months;
a smoking history that was either recent (12 months prior to
screening) or equivalent to  10 pack-years (i.e. at least
20 cigarettes/day for 10 years); significant non-reversible
active pulmonary disease; and clinically significant respi-
ratory tract infection within the 4 weeks prior to screening.
Assessments
The primary endpoint was the mean change in pre-morning
dose FEV1 from baseline to the end of treatment. The co-
primary endpoint was the mean change in FEV1 from pre-
morning dose at baseline to 2 h post-morning dose at the end
of treatment. Secondary endpoints included:mean12-h FEV1
area under curve (AUC; in a subset of 300 patients); discon-
tinuations due to lack of treatment efficacy; PEFR; forced
vital capacity (FVC); forced expiratory flow at 25%, 50% and
75% of the volume to be exhaled (FEF25, FEF50, FEF75,
FEF25e75); asthma symptom scores; asthma symptom-free
days; sleep disturbance scores; awakening-free nights;
asthma control days (defined as days with an asthma
symptom score of 0 [no symptoms], a sleep disturbance score
of 0 [slept through the night] and no inhalations of rescue
medication); asthma exacerbations; rescue medication use;
rescue medication-free days; patient assessment of study
medication; and score on the Asthma Quality of Life Ques-
tionnaire (AQLQ).21 Lung function assessments, reviews of
patients’ electronic diaries and safety assessments were
madeatweeks 2, 4, 6 and8.At each visit, patients completed
a lung function test before and 2 h (þ/ 15 min) after
receiving their morning dose.Safety assessments included the incidence and type of
spontaneously reported AEs, vital signs, laboratory tests
and 12-lead electrocardiograms.Statistical analysis
The primary objective was to demonstrate non-inferiority of
fluticasone/formoterol (500/20 mg, b.i.d.) versus fluticasone
þ formoterol based on the mean change in pre-morning dose
FEV1 frombaseline to the end of the 8-week treatment period
(primary endpoint). The co-primary objective was to demon-
strate non-inferiority of fluticasone/formoterol (500/20 mg,
b.i.d.) versus fluticasone þ formoterol as assessed by mean
change in FEV1 from pre-morning dose at baseline to 2 h post-
morning dose at the end of treatment (week 8). Secondary
objectives included demonstration of superiority of flutica-
sone/formoterol (500/20 mg, b.i.d.) versus fluticasone treat-
ment alone and fluticasone/formoterol dose response.
The intent-to-treat (ITT) population included all
patients randomized who received at least one dose of
study treatment and had at least one post-dose primary
efficacy (FEV1) measurement. The per protocol set (PPS)
was defined as all ITT patients who completed the study
without major protocol violations affecting the primary
efficacy endpoint. Major protocol violations leading to
exclusion from PPS were decided before unblinding the
study. The safety set (SS) was defined as all patients who
were randomized to receive study treatment and had at
least one post-dose safety assessment.
Non-inferiority for the primary and co-primary efficacy
endpoints was assessed in the PPS using an analysis of
covariance (ANCOVA) with treatment as a factor, baseline
value and asthma severity as linear covariates, and centre
as a random effect. Non-inferiority for the primary and co-
primary efficacy endpoints would be concluded if the lower
limit of the 95% confidence interval (CI) for the difference
between treatments was  0.2 L, demonstrated by an
associated P < 0.05. A total sample size of 572 randomized
patients (121 per treatment group in the PPS) would ach-
ieve 93% power to demonstrate a treatment difference of
 0.2 L.
As a supportive analysis, the primary and co-primary
endpoint analysis was also performed on the ITT population
(last observation carried forward [LOCF] method). Superi-
ority for the primary and co-primary endpoints and for
fluticasone/formoterol (500/20 mg, b.i.d.) versus flutica-
sone, as well as the fluticasone/formoterol dose response,
were assessed for the ITT set using the same ANCOVA.
ANCOVA was also used to analyse the other secondary
efficacy parameters.
Use of rescue medication during the study was analysed
using a Wilcoxon rank sum test. Patient assessment of
asthma medication was analysed using a proportional odds
model with treatment group as a factor. The difference in
percentages and 95% CI was calculated for discontinuations
due to lack of efficacy, non-inferiority was concluded if the
upper limit of the 95% CI was  10 %. Asthma exacerbations
were analysed using a Fisher’s exact test. All other
endpoints were summarized using descriptive statistics. All
hypothesis tests were 2-sided and conducted at the 5% error
level. Other data are reported as means and 95% CI.
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differences between treatment groups in the risk for
discontinuations, an ANCOVA analysis of pre- and post-dose
FEV1 at each visit, and an analysis of FEV1 AUC at each time
point.
Results
Patients
Of the 620 patients randomized, 540 (87.1%) completed the
study (Fig. 1). Baseline characteristics were similar
between the four treatment groups (Table 1). All but 7
patients (1.1%, distributed relatively evenly across treat-
ment groups, and not considered a major protocol devia-
tion) were taking ICSs at screening, with a median daily
dose of 500 mg. LABAs were being taken at screening by
75.5% of all patients in the four treatment groups (range
72.3e79.5%). Concomitant non-rescue medication was
being taken by all but 1 patient at screening. There were
no noteworthy differences between the four treatment
groups apart from a higher number of patients in the flu-
ticasone/formoterol (100/10 mg, b.i.d.) and fluticasone
groups taking calcium channel blockers, reflecting higher
rates of hypertension in these groups. Good compliance
with study medication was recorded for patients in all four
treatment groups (over 90% of patients in each group
achieved at least 75% compliance with study medication,
ITT population).
Efficacy parameters
Fluticasone/formoterol (500/20 mg, b.i.d.) was at least as
effective as fluticasone þ formoterol, with an increase in
mean pre-morning dose FEV1 of 0.345 L (n Z 133) and
0.284 L (n Z 140), respectively from baseline to week 8
(PPS; least-squares [LS] mean of the treatment difference:Figure 1 Participant flow. Fluticasone/formoterol Z fluticasone
sone þ formoterol Z fluticasone and formoterol administered con0.060 L; 95% CI: 0.059, 0.180; P < 0.001; Fig. 2a). Results
were similar for the ITT population with an increase in
mean pre-morning dose FEV1 of 0.346 L (n Z 154) with
fluticasone/formoterol (500/20 mg, b.i.d.) and 0.267 L
(n Z 156) with fluticasone þ formoterol, from baseline to
week 8 (LS mean of the treatment difference: 0.079 L; 95%
CI: 0.032, 0.190; P < 0.001; Fig. 2b).
Fluticasone/formoterol (500/20 mg, b.i.d.) was also non-
inferior to fluticasone þ formoterol in terms of change in
mean FEV1 from baseline pre-morning dose to 2 h post-
morning dose at week 8 (the co-primary efficacy param-
eter; Fig. 3a) with a mean increase of 0.518 L and 0.500 L,
respectively (PPS; LS mean of the treatment difference:
0.018 L; 95% CI: 0.098, 0.135; P < 0.001). Again, results
were similar for the ITT population with a mean increase of
0.517 L with fluticasone/formoterol (500/20 mg, b.i.d.) and
0.477 L with fluticasone þ formoterol (LS mean of the
treatment difference: 0.040 L; 95% CI: 0.069, 0.149;
P < 0.001; Fig. 3b).
Similar results were observed with fluticasone/for-
moterol (500/20 mg, b.i.d.) and fluticasone þ formoterol
on the secondary efficacy parameters (Table 2). Non-
inferiority of fluticasone/formoterol (500/20 mg, b.i.d.) to
fluticasone þ formoterol was formally shown for discon-
tinuation due to lack of efficacy. A KaplaneMeier survival
curve for the ITT population to identify differences
between treatment groups in the risk of discontinuations
revealed that fluticasone/formoterol (500/20 mg, b.i.d.)
had the lowest risk of discontinuation (Fig. 4). A similar
proportion of patients in the fluticasone þ formoterol
group (35.3%) compared with the fluticasone/formoterol
(500/20 mg, b.i.d.) group (35.1%) experienced at least
1 mild or moderate asthma exacerbation (P Z 1.0),
during the randomized treatment period. Severe asthma
exacerbations were experienced by only 3 patients (1.9%)
in the fluticasone/formoterol (500/20 mg, b.i.d.) group
and by none in the fluticasone þ formoterol group (P Z
0.121).and formoterol in a single dose inhaler combination; flutica-
currently in separate inhalers.
Table 1 Characteristics of study participants at screening (intent-to-treat population).
Parameter Fluticasone
/formoterol
(500/20 mg, b.i.d.)
Fluticasone
þ formoterol
(500 mg þ 24 mg, b.i.d.)
Fluticasone
/formoterol
(100/10 mg, b.i.d.)
Fluticasone
(500 mg, b.i.d.)
Total
n Z 154 n Z 156 n Z 155 n Z 155 n Z 620
Age [years] Mean (SD) 50.5 (14.4) 49.6 (12.8) 48.0 (13.9) 48.5 (14.9) 49.1 (14.0)
Median 53.0 52.0 50.0 50.0 51.5
Range 18e78 19e76 18e80 18e78 18e80
Gender
Male n (%) 56 (36.4) 67 (42.9) 60 (38.7) 61 (39.4) 244 (39.4)
Female n (%) 98 (63.6) 89 (57.1) 95 (61.3) 94 (60.6) 376 (60.6)
Race
Caucasian n (%) 141 (91.6) 142 (91.0) 143 (92.3) 143 (92.3) 569 (91.8)
Black n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Asian n (%) 13 (8.4) 14 (9.0) 12 (7.7) 12 (7.7) 51 (8.2)
Duration of asthma
< 10 years n (%) 83 (53.9) 79 (50.6) 81 (52.3) 80 (51.6) 323 (52.1)
 10 years n (%) 71 (46.1) 77 (49.4) 74 (47.7) 75 (48.4) 297 (47.9)
FEV1 % predicted
a [%]
Mean (SD) 58.7 (10.9) 58.0 (10.0) 57.4 (10.2) 59.6 (10.1) 58.4 (10.3)
Median 58.4 56.7 57.0 59.2 58.1
Range 36e99 41e83 32e91 35e79 32e99
FEV1
a [L]
Mean (SD) 1.706 (0.547) 1.739 (0.541) 1.734 (0.576) 1.789 (0.568) 1.742 (0.558)
Median 1.625 1.685 1.680 1.660 1.660
Range 0.71e3.37 0.89e3.13 0.69e3.49 0.66e3.36 0.66e3.49
b.i.d.Z twice daily; FEV1Z forced expiratory volume in first second; fluticasone/formoterol Z fluticasone and formoterol in a single
dose inhaler combination; fluticasone þ formoterol Z fluticasone and formoterol administered concurrently in separate inhalers;
formoterol Z formoterol fumarate; SD Z standard deviation.
a Pre-salbutamol value.
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superiority to fluticasone alonewith an increase frombaseline
in mean pre-morning dose FEV1 to 2 h post-morning dose at
week 8 of 0.517 L (nZ 154) and 0.396 L (nZ 155), respectively
(ITT population; LSmean of the treatment difference: 0.120 L;
95% CI: 0.011, 0.230; P Z 0.032) (Fig. 3b). Treatment with
fluticasone/formoterol (500/20 mg, b.i.d.) resulted in a larger
increase in pre-morning dose FEV1 compared with treatment
with fluticasone alone, but the difference between the two
treatment groups was not statistically significant (ITT pop-
ulation; LSmean of the treatment difference: 0.023 L; 95% CI:
0.088, 0.135; P Z 0.681). A post hoc analysis revealed
superiority of fluticasone/formoterol (500/20 mg, b.i.d.) to
fluticasone alonewith respect to change in FEV1 frompre-dose
to 1 and 2 h post-dose (ITT population; LS mean of the treat-
ment difference at 1 h: 0.140 L, 95% CI: 0.042, 0.237;
PZ0.005; LSmeanof the treatmentdifferenceat 2 h: 0.116 L,
95%CI: 0.019, 0.213;PZ0.019). Data fromthe12-h serial FEV1
AUC analysis also supported superior efficacy of fluticasone/
formoterol (500/20 mg, b.i.d.) versus fluticasone. Treatment
with fluticasone/formoterol (500/20 mg, b.i.d.) resulted in
numerically larger improvements in FEV1 than treatment with
fluticasone alone at baseline and week 8 (ITT population, not
statistically significant).Discontinuationdue to lackofefficacy
was tested for non-inferiority/superiority, and fluticasone/
formoterol (500/20 mg, b.i.d.) was found to be superior tofluticasone alone for this parameter (3.9% versus 11.0%
patients in the two groups, respectively, 95% CI:12.9,1.3;
Fig. 4). Superiority of the combination was also demonstrated
for: evening PEFR (LS mean of the treatment difference:
14.1 L/min; 95% CI: 1.3, 27.0; P Z 0.031); asthma symptom
score (LS mean of the treatment difference: 0.16; 95% CI:
0.29, 0.02; P Z 0.020); proportion of symptom-free days
(LS mean of the treatment difference: 8.69%; 95% CI: 0.39,
17.00; P Z 0.040); percentage of awakening-free nights (LS
mean of the treatment difference: 6.67%; 95% CI: 0.51, 12.83;
P Z 0.034); assessment of study medication (odds ratio of
2.119, 95% CI: 1.377, 3.262); and AQLQ (LS mean of the treat-
ment difference: 0.22 units; 95% CI: 0.01, 0.42; PZ 0.036).
Larger increases in mean FEV1 from pre-morning dose on
day 0 to pre-morning dose at week 8 were observed for flu-
ticasone/formoterol (500/20 mg, b.i.d.) than for fluticasone/
formoterol (100/10 mg, b.i.d.). ANCOVA did not demonstrate
significance in the difference between treatments for this
endpoint, but a post hoc analysis revealed superiority
(P < 0.05) of fluticasone/formoterol (500/20 mg, b.i.d.)
overall (including all study visits) and at each study visit
except week 8. Fluticasone/formoterol (500/20 mg, b.i.d.)
was superior to fluticasone/formoterol (100/10 mg, b.i.d.)
for discontinuations due to lack of efficacy (3.9% versus 11.6%
patients in the 2 groups, respectively, 95% CI: 13.6, 1.8;
Fig. 4). Superiority of the higher dose was also demonstrated
ab
Figure 2 Mean change in pre-morning dose FEV1 from base-
line to week 8 including all study visits in a) the per protocol
set and b) the intent-to-treat population. * Statistical non-
inferiority of fluticasone/formoterol (500/20 mg b.i.d.) to
fluticasoneþ formoterol (500 mgþ 24 mg, b.i.d.), demonstrated
by ANCOVA F-test for treatment. y Statistical confirmation of
null hypothesis of no treatment difference, demonstrated by
ANCOVA F-test for treatment. n numbers refer to ITT population
at baseline (week 0). ANCOVA Z analysis of covariance;
b.i.d. Z twice daily; FEV1 Z forced expiratory volume in
first second; fluticasone/formoterol Z fluticasone and for-
moterol in a single dose inhaler combination; fluticaso-
ne þ formoterol Z fluticasone and formoterol administered
concurrently in separate inhalers.
a
b
Figure 3 Mean change in pre-morning dose FEV1 at baseline to
2 h post-morning dose at all study visits to week 8 in a) the per
protocol set and b) the intent-to-treat population. * Statistical
non-inferiority of fluticasone/formoterol (500/20 mg b.i.d.) to
fluticasoneþ formoterol (500mgþ24mg,b.i.d.),demonstratedby
ANCOVA F-test for treatment. y Statistical confirmation of null
hypothesis of no treatment difference, demonstrated by ANCOVA
F-test for treatment. n numbers refer to ITT population at base-
line (week 0). ANCOVAZ analysis of covariance; b.i.d.Z twice
daily; FEV1 Z forced expiratory volume in first second; flutica-
sone/formoterol Z fluticasone and formoterol in a single dose
inhaler combination; fluticasoneþ formoterolZ fluticasone and
formoterol administered concurrently in separate inhalers.
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sleep disturbance scores (LS mean of the treatment differ-
ence: 0.12 units; 95% CI: 0.20, 0.04; P Z 0.005),
proportion of awakening-free nights (LS mean of the treat-
ment difference: 9.87%; 95% CI: 3.66, 16.08; PZ 0.002) and
assessment of studymedication (odds ratio at week 8: 1.775,
95% CI: 1.160, 2.717).
Safety parameters
Both doses of fluticasone/formoterol had similar safety and
tolerability profiles to fluticasoneþ formoterol (Table 3). The
overall AE rates in the SS were 19.5%, 19.9%, 18.7% and 14.2%
in the fluticasone/formoterol (500/20 mg, b.i.d.),
fluticasoneþ formoterol, fluticasone/formoterol (100/10 mg,
b.i.d.) and fluticasone groups, respectively. The majority of
AEs were mild or moderate in intensity. In all treatment
groups, the most common AEs were nasopharyngitis, head-
ache, pharyngitis, asthma and viral infection. The incidence
of AEs considered to be probably or possibly related to
treatment was 3 in the fluticasone/formoterol (500/20 mg,
b.i.d.) group, 2 in the fluticasoneþ formoterol group, 8 in the
fluticasone/formoterol (100/10 mg, b.i.d.) and 5 in the fluti-
casone group. The incidence of AEs considered to be unlikelyrelated to treatment was 2 in the fluticasone/formoterol
(500/20 mg, b.i.d.) group, 1 in the fluticasone þ formoterol
group, and 5 in the fluticasone/formoterol (100/10 mg,
b.i.d.). Overall, 6 patients (1.0%) were withdrawn due to AEs
(Table 3). Discontinuation due to lack of therapeutic effect
was themost common reason for withdrawal in all treatment
groups. In the ITT population, 6 patients (3.9%) in the fluti-
casone/formoterol (500/20 mg, b.i.d.) group, 12 patients
(7.7%) in the fluticasone þ formoterol group, 18 patients
(11.6%) in the fluticasone/formoterol (100/10 mg, b.i.d.) and
17 patients (11.0%) in the fluticasone alone group dis-
continued the treatment phase due to lack of efficacy.
Discussion
This study compared the efficacy and safety of fluticasone/
formoterol (500/20 mg, b.i.d.) with fluticasoneþ formoterol
in treating patients with moderate-to-severe asthma. Effi-
cacy of the individual components is already documented
extensively in the literature.16,22e24 The combination has
nowbeendevelopedas a single inhaler therapy and this study
has demonstrated that fluticasone/formoterol (500/20 mg,
b.i.d.) is at least as effective as its individual components
administered concurrently. Treatment with fluticasone/
Table 2 Summary of secondary endpoint data for fluticasone/formoterol 500/20 mg, b.i.d. and fluticasone þ formoterol
(intent-to-treat population). No statistically significant differences were demonstrated between the fluticasone/formoterol
500/20 mg, b.i.d. and fluticasone þ formoterol groups for any of the parameters listed in this table. Increases between baseline
and week 8 were also similar between the two treatment groups for daily FEV1, FVC, FEF25, FEF50, FEF75 and FEF25e75, but
statistical tests were not performed for these parameters.
Parameter Fluticasone/formoterol
(500/20 mg, b.i.d.) n Z 154
Fluticasone þ formoterol
(500 mg þ 24 mg, b.i.d.) n Z 156
12-h serial FEV1 AUC (L*hours)
Baseline (mean  SD) 23.9  7.76 25.3  7.76
End of study (mean  SD) 25.3  9.60 26.9  8.75
Discontinuations due to lack of efficacy, n (%) 6 (3.9) 12 (7.7)
Morning pre-dose peak flow rates (L/min)
Baseline (mean  SD) 310.7  124.5 304.6  121.6
End of study (mean  SD) 345.2  125.7 349.4  123.2
Evening pre-dose peak flow rates (L/min)
Baseline (mean  SD) 315.5  123.1 312.3  121.4
End of study (mean  SD) 347.7  129.7 355.8  119.4
Asthma symptom scoresa
Baseline (mean  SD) 1.17  0.61 1.12  0.62
End of study (mean  SD) 0.38  0.59 0.43  0.72
Percentage of symptom-free daysa
Baseline (mean  SD) 16.1  22.9 18.0  24.8
End of study (mean  SD) 65.8  37.9 63.9  38.0
Mean sleep disturbance scoresa
Baseline (mean  SD) 0.65  0.57 0.57  0.55
End of study (mean  SD) 0.14  0.37 0.11  0.29
Percentage of awakening-free nightsa
Baseline (mean  SD) 46.1  37.4 49.5  37.1
End of study (mean  SD) 84.4  25.8 84.0  24.7
Percentage of asthma control daysa
Baseline (mean  SD) 9.00  16.73 7.97  15.67
End of study (mean  SD) 53.06  38.33 52.47  37.29
Number of uses of rescue medication (median)b 0.3 0.2
Percentage of rescue medication-free daysa
Baseline (mean  SD) 15.7  21.0 13.4  18.5
End of study (mean  SD) 68.1  37.5 68.1  37.4
Subjects assessment of study
medication as very good or good (%)
85.1 83.9
AQLQ
Baseline (mean  SD) 4.42  0.89 4.57  0.99
End of study (mean  SD) 5.34  1.07 5.30  1.00
AQLQZ Asthma Quality of Life Questionnaire; AUCZ area under curve; FEF25, FEF50, FEF75, FEF25e75Z forced expiratory flow at 25%,
50% and 75% of the volume to be exhaled; FEV1 Z forced expiratory volume in first second; fluticasone/formoterol Z fluticasone and
formoterol in a single dose inhaler combination; fluticasone þ formoterol Z fluticasone and formoterol administered concurrently in
separate inhalers; formoterol Z formoterol fumarate; FVC Z forced vital capacity; SD Z standard deviation.
a Measurements were categorized into visits for each subject using the percentage of asthma control days for the 7 days prior to each
visit.
b Number of uses of rescue medication standardized by dividing by the number of days from date of randomization to date of last dose.
680 A. Bodzenta-Lukaszyk et al.formoterol was dose-dependent, as shown for several effi-
cacy parameters. A post hoc analysis of fluticasone/for-
moterol (500/20 mg, b.i.d.) andfluticasone/formoterol (100/
10 mg, b.i.d.) revealed that pre-dose FEV1 was superior for
the higher dose at weeks 2, 4 and 6, but not at week 8,possibly due to a higher proportion of patients discontinuing
the study prematurely in the lower dose group.
Effectiveness of any inhaled asthma therapy in clinical
practice is dependent on a number of factors including drug
efficacy, delivery, correct device handling, inhalation
Figure 4 Time to discontinuation due to lack of efficacy
(KaplaneMeier survival curve; intent-to-treat population).
* Statistically significant difference (P < 0.05 based on Wald chi-
square) versus fluticasone/formoterol (500/20 mg, b.i.d.) for time
to discontinuation due to lack of efficacy. Difference was not
statistically different between fluticasone þ formoterol
(500 mg þ 24 mg, b.i.d.) and fluticasone/formoterol (500/20 mg,
b.i.d.). b.i.d.Z twicedaily;fluticasone/formoterolZfluticasone
and formoterol in a single dose inhaler combination; fluticaso-
ne þ formoterol Z fluticasone and formoterol administered
concurrently in separate inhalers; formoterol Z formoterol
fumarate.
Fluticasone/formoterol combination vs. individual components 681technique and adherence. The combination tested benefits
from the fact that fluticasone is one of the most active and
long-lasting ICSs available and formoterol is the most
rapidly acting LABA. There may also be potential for the
fluticasone/formoterol combination to increase patient
adherence to their therapy regimen. Patients may perceive
the relief of asthma symptoms with formoterol more
rapidly than with other LABAs,17,25,26 providing motivation
to adhere to their therapy regimen.18 It has been estab-
lished that the large majority of patients want to feel
immediate relief of asthma symptoms when they use their
asthma medication.11 In addition, the delivery device for
fluticasone/formoterol is a pMDI, which is familiar to most
patients and delivers an aerosol of particles for consistent
dosing, without the requirement for a minimum threshold
inspiratory effort.18,27Table 3 Summary of adverse events (safety set).
Fluticasone
/formoterol
(500/20 mg, b.i.d.)
n Z 154
Patients with 1 AEs (%) 30 (19.5)
Patients with 1 mild AEs (%) 20 (13.0)
Patients with 1 moderate AEs (%) 9 (5.8)
Patients with 1 severe AEs (%) 2 (1.3)
Patients with 1 treatment-related AEs (%) 5 (3.2)
Patients withdrawn from
treatment due to AEs (%)
3 (1.9)
Patients with 1 SAEs (%) 0 (0.0)
Patients who died (%) 0 (0.0)
AE Z adverse event; fluticasone/formoterol Z fluticasone and
sone þ formoterol Z fluticasone and formoterol administered concuThe safety profiles of fluticasone and formoterol are well
established. Pharmacokinetic studies have shown that fluti-
casone/formoterol combination therapy has a pharmacoki-
netic profile indicative of a similar or slightly lower potential
for systemic exposure versus its individual components.28 Our
study showed that fluticasone/formoterol has a similar safety
and tolerability profile to its components, administered
concurrently.
It is noteworthy that significantly more patients whose
asthma was not appropriately controlled were discontinued
prematurely due to lack of efficacy in the fluticasone/for-
moterol (100/10 mg, b.i.d.) and fluticasone groups than in
the fluticasone/formoterol (500/20 mg, b.i.d.) group. For
a number of parameters, results were numerically in favour
of fluticasone/formoterol (500/20 mg, b.i.d.) over flutica-
sone/formoterol (100/10 mg, b.i.d.) or fluticasone alone,
but the differences did not achieve statistical significance
(for example, comparison of the two fluticasone/for-
moterol dose groups for the primary endpoint). It is
reasonable to expect that the observed differences in
efficacy outcomes between the fluticasone/formoterol
(500/20 mg, b.i.d.) versus the fluticasone/formoterol (100/
10 mg, b.i.d.) and fluticasone alone groups might have been
larger if more patients in the latter groups had continued to
the end of the study.
In conclusion, this study has demonstrated that the flu-
ticasone/formoterol (500/20 mg, b.i.d.) combination is at
least as effective as its components administered concur-
rently in separate inhalers. Fluticasone/formoterol (500/
20 mg, b.i.d.) also demonstrated superior efficacy to its ICS
component alone on various efficacy parameters including
the co-primary endpoint, discontinuations due to lack of
efficacy, evening PEFR, asthma symptom score, symptom-
free days, awakening-free nights, patient assessment of
study medication and AQLQ. The efficacy of the combina-
tion was dose-dependent, with superiority of fluticasone/
formoterol (500/20 mg, b.i.d.) over fluticasone/formoterol
(100/10 mg, b.i.d.) on parameters such as change in mean
pre-morning dose FEV1 (overall, including all study visits;
post hoc analysis), discontinuations due to lack of efficacy,
sleep disturbance scores, awakening-free nights and
patient assessment of study medication. This ICS/LABAFluticasone
þ formoterol
(500 mg þ 24 mg, b.i.d.)
Fluticasone
/formoterol
(100/10 mg, b.i.d.)
Fluticasone
(500 mg, b.i.d.)
n Z 156 n Z 155 n Z 155
31 (19.9) 29 (18.7) 22 (14.2)
20 (12.8) 22 (14.2) 11 (7.1)
12 (7.7) 9 (5.8) 10 (6.5)
0 (0.0) 2 (1.3) 3 (1.9)
3 (1.9) 6 (3.9) 4 (2.6)
1 (0.6) 0 (0.0) 2 (1.3)
1 (0.6) 0 (0.0) 1 (0.6)
0 (0.0) 0 (0.0) 0 (0.0)
formoterol in a single dose inhaler combination; flutica-
rrently in separate inhalers; SAE Z serious adverse event.
682 A. Bodzenta-Lukaszyk et al.combination has now been developed as a single inhaler
therapy in an HFA pMDI, presenting an additional effica-
cious treatment option for adults with moderate-to-severe
persistent, reversible asthma who require a step up from
ICS therapy or are already receiving treatment with an
existing fixed-dose combination.
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